All In Biotech

Drug Trial Radar · NCT07392957

Safety and Efficacy of CTX-009 With or Without CTX-471 for Recurrent Glioblastoma

A Phase IB/II Open-label Study of the Safety and Preliminary Efficacy of CTX-009 Administered Either as a Monotherapy or in Combination With CTX-471 in Patients With Recurrent Glioblastoma

Last checked: Nov 19, 2026Latest source record: Jun 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

54

Planned (sponsor's estimate)

Start

Jun 16, 2026

Primary completion

Jun 30, 2029

Study completion Jun 30, 2031

Sponsor

Lead sponsor
Washington University School of MedicineAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Compass Therapeutics
First posted
Feb 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase IB/II, open-label study evaluating CTX-009 as monotherapy and in combination with CTX-471. The study evaluates the safety and efficacy of the monotherapy and the combination in patients with recurrent glioblastoma. The study tests the hypothesis that treatment with CTX-009 alone or in combination with CTX-471 will lead to enhanced tumor control and prolongation of overall survival of patients with recurrent glioblastoma. CTX-009 expands on existing anti-angiogenic therapies by ablating key compensatory and resistance mechanisms to bevacizumab, CTX-471 restores local immune reactivity through activation of costimulatory immune mediators. Combination of these two agents may further impair tumor proliferation through synergistic effects on the tumor microenvironment

Conditions

  • Glioblastoma

Interventions

  • CTX-009Drug

    CTX-009 will be given intravenously over the course of 60 minutes (+/- 5 minutes) on an outpatient basis every 2 weeks of a 28-day cycle.

  • CTX-471Drug

    CTX-471 will be given intravenously over the course of 30 minutes (-5/+10) on an outpatient basis every 2 weeks of a 28-day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase IB Arm 1: Toxicity as measured by number of participants with adverse eventsTime frame: Start of treatment through 60 days after treatment (estimated to be 14 months)
  2. Phase IB Arm 1: Recommended Phase 2 Dose (RP2D)Time frame: Start of treatment through completion of cycle 1 (each cycle is 28 days)
  3. Phase IB Arm 2: Toxicity as measured by number of participants with adverse eventsTime frame: Start of treatment through 60 days after treatment (estimated to be 14 months)
  4. Phase II Arm 1: Overall survival rate at 12 months (OS12)Time frame: 12 months
  5. Phase II Arm 2: Overall survival rate at 12 months (OS12)Time frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Washington University School of Medicine

    St Louis, Missouri · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.